Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-12
- Last Posted Date
- 2022-06-21
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 54
- Registration Number
- NCT02770391
- Locations
- 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
- Conditions
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 24
- Registration Number
- NCT02721979
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-03-09
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 196
- Registration Number
- NCT02703623
- Locations
- 🇺🇸
MD Anderson in Katy, Houston, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson in Sugar Land, Sugar Land, Texas, United States
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT02578797
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
- Conditions
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1503
- Registration Number
- NCT02531516
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1052
- Registration Number
- NCT02489318
Micro RNAs to Predict Response to Androgen Deprivation Therapy
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 42
- Registration Number
- NCT02366494
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 982
- Registration Number
- NCT02257736
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02106507
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Aragon Pharmaceuticals, Inc.
- Target Recruit Count
- 1207
- Registration Number
- NCT01946204
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.